Medical Companies

Large Scale Biology Corporation

medical products — Sat, 05 Dec 2009 18:13:55 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Large Scale Biology Corporation’s (LSBC) goal is to develop, manufacture and commercialize plant-made pharmaceutical proteins and vaccines. LSBC has successfully garnered an international reputation as an innovator in biomanufacturing. Driven by its unique GENEWARE® RNA plant viral gene expression technology, LSBC has taken integration of plant-made pharmaceuticals from gene to production further than any other company. GENEWARE® technology is complemented by a full commercial-scale capability to produce, extract, purify, finish and fill a wide range of pharmaceutical proteins. LSBC’s proprietary core technologies radically extend the power of product development, improvement and ( www.lsbc.com )

Large Scale Biology Corporation
3333 Vaca Valley Parkway
Vacaville, California 95688
USA

Tel: (707) 469-2316
Fax: (707) 446-3917

Ceragenix Pharmaceuticals , Inc.

medical products — Sat, 05 Dec 2009 18:13:25 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Ceragenix is developing next generation prescription therapies based on its platform of surface active technologies – skin Barrier Repair Technology (BRT) and a new class of anti-infectives called CerageninsÔ. Our goal is to become a market leader in developing novel and high-impact therapies and medical products for selected markets in infectious disease and dermatology. The Company seeks to enjoy early revenue opportunities from its first and recently FDA-approved skin Barrier Repair Therapy product EpiCeram® and will use this cash flow to focus on development of Ceragenin product candidates for the larger anti-infectives market in which there continues to be a significant need for novel antibiotics with low potential for ( www.ceragenix.com )

Ceragenix Pharmaceuticals , Inc.
1444 Wazee Street Suite 210
Denver, Colorado 80202
USA

Tel: (720) 946-6440
Fax: (303) 534-1800

ADERIS Pharmaceuticals Inc

medical products — Sat, 05 Dec 2009 18:12:19 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Aderis Pharmaceuticals is a private, biopharmaceutical company engaged in small molecule drug development to treat central nervous system, cardiovascular and renal disorders. The Company currently has four product candidates in six clinical development programs. Aderis Pharmaceuticals has a strategic alliance with Schwarz Pharma AG, for the development of rotigotine CDS, a proprietary dopamine agonist formulated as a once-a-day, continuous delivery, transdermal patch. Rotigotine completed Phase III trials for Parkinson’s disease and is in Phase IIb for the treatment of Restless Legs Syndrome. The Company also has corporate collaborations with Fujisawa Healthcare, Inc. and King ( www.aderis.com )

ADERIS Pharmaceuticals Inc
85 Main Street
Hopkinton, Massachusetts 01748
USA

Tel: (508) 497-2300
Fax: (508) 497-9553

Trubion Pharmaceuticals, Inc

medical products — Sat, 05 Dec 2009 18:11:53 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Trubion Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of novel medicines to treat inflammatory disease and cancer. The company utilizes proprietary technology to develop drugs that are safer and more effective than currently available therapies. Trubion has developed a proprietary product engine to create a novel class of compounds known as SMIPsÔ (Small Modular ImmunoPharmaceuticals). SMIPs are highly-specific, single-chain polypeptides designed with optimized target binding and effector functions to overcome limitations of therapeutic antibodies and antibody alternatives. SMIPs are significantly smaller than antibodies and can reach sites unavailable to larger ( www.trubion.com )

Trubion Pharmaceuticals, Inc
2401 14Th Avenue Suite 1050
Seattle, Washington 98121
USA

Tel: (206) 838-0500
Fax: (206) 838-0503

Alexion Pharmaceuticals , Inc.

medical products — Sat, 05 Dec 2009 18:11:24 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Alexion Pharmaceuticals is a biotechnology company working to develop and deliver life-changing drug therapies for patients with serious and life- threatening medical conditions. Alexion is engaged in the discovery and development of therapeutic products aimed at treating patients with a wide array of severe disease states, including hematologic diseases, cancer, and autoimmune disorders. Alexion’s lead product candidate, SolirisÔ (eculizumab), is currently undergoing evaluation in several clinical development programs, including for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Under the Special Protocol Assessment (SPA) process, the FDA has agreed to the design of protocols for the two phase III trials of SolirisÔ (eculizumab) in PNH ( www.alexionpharm.com )

Alexion Pharmaceuticals , Inc.
352 Knotter Drive
Cheshire, Connecticut 06410
USA

Tel: (203) 272-2596
Fax: (203) 271-8190

AlphaVax , Inc.

medical products — Sat, 05 Dec 2009 18:06:22 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
AlphaVax is developing a new vaccine technology with broad applications against infectious disease, cancer and biodefense threats which has the potential to redefine vaccines and the role they play in medicine. AlphaVax uses a specialized viral vector system to make alphavirus replicon vaccines called alphavaccines, which have shown excellent protection in multiple models for infectious disease and cancer. Since 1998, the company has raised more than $110 million, with 75% coming from corporate partner and grant funding, and has advanced the alphavaccine platform system from the academic laboratory to human clinical trials, establishing the technical, regulatory, and manufacturing foundation for commercializing ( www.alphavax.com )

AlphaVax , Inc.
P.O. Box 110307
Research Triangle Park, North Carolina 27709-0307
USA

Tel: (919) 595-0400
Fax: (919) 595-0401

La Jolla Pharmaceutical Company

medical products — Sat, 05 Dec 2009 18:05:58 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
La Jolla Pharmaceutical Company is a biotechnology company developing therapeutics for antibody-mediated autoimmune diseases and inflammation afflicting several million people around the world. The Company is developing Riquent® for the treatment of lupus kidney disease, a leading cause of sickness and death in patients with lupus. The Company is also developing small molecules to treat various other autoimmune and inflammatory conditions. The Company’s common stock is traded on The Nasdaq Stock Market under the symbol LJPC. ( www.ljpc.com )

La Jolla Pharmaceutical Company
6455 Nancy Ridge Drive
San Diego, California 92121-2249
USA

Tel: (858) 452-6600
Fax: (858) 625-0155

ThromboGenics Ltd.

medical products — Sat, 05 Dec 2009 18:05:33 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
ThromboGenics is a biopharmaceutical company focused on the development of therapeutics for conditions related to the vascular system. The Company has used its in house expertise to build a significant pipeline of promising drug candidates, a number of which are in clinical trials. The Company is focused on developing new medicines to treat visual disorders, cardiovascular diseases, and cancer, conditions which result from abnormalities to the vascular system. ThromboGenics’ lead product is microplasmin, a stable proteolytic enzyme which is in Phase II trials for eye disease and thrombotic disease. The Company plans to show proof-of-concept for its products by taking them through to completion of Phase II clinical ( www.thrombogenics.com )

ThromboGenics Ltd.
500 7Th Avenue 10Th Floor B
New York, New York 10018
USA

Tel: (212) 201-0920
Fax: (212) 201-0921

SGX Pharmaceuticals , Inc.

medical products — Sat, 05 Dec 2009 18:05:09 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
SGX Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The company’s lead product candidate, Troxatyl(TM), is currently being evaluated in a pivotal Phase II/III trial for the treatment of third-line acute myelogenous leukemia. SGX has developed a pipeline of oncology drug candidates based on its enabling, proprietary FAST(TM) drug discovery platform, including next generation BCR-ABL inhibitors currently being developed in partnership with Novartis. FAST allows for the rapid identification of novel, potent and selective small molecule compounds for well validated but challenging targets. ( www.sgxpharma.com )

SGX Pharmaceuticals , Inc.
SGX Pharmaceuticals, Inc. 10505 Roselle Street
San Diego, California 92121
USA

Tel: (858) 558-4850
Fax: (858) 558-4859

Panacea Pharmaceuticals , Inc.

medical products — Sat, 05 Dec 2009 18:04:42 +0000

Industry: Drug Manufacturing, Pharmaceuticals, Biotechnology
Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company’s product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson’s Disease, and Alzheimer’s Disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies. Panacea Laboratories is a division of Panacea Pharmaceuticals, Inc. ( www.panaceapharma.com )

Panacea Pharmaceuticals , Inc.
207 Perry Parkway Suite #2
Gaithersburg, Maryland 20877
USA

Tel: (240) 243-8000
Fax: (240) 465-0450